Itrawave 100 Capsule contains Itraconazole 100 mg, an antifungal agent belonging to the triazole class, indicated for the treatment of a variety of fungal infections. Itraconazole works by inhibiting the synthesis of ergosterol, a vital component of fungal cell membranes, thereby disrupting membrane integrity and leading to fungal cell death. This medication is commonly prescribed for conditions such as aspergillosis, blastomycosis, histoplasmosis, onychomycosis, and other systemic and superficial mycoses caused by susceptible fungi. Itrawave 100 Capsule is administered orally and demonstrates good bioavailability when taken with food, enhancing absorption. The drug undergoes hepatic metabolism primarily via the cytochrome P450 system, necessitating caution in patients with liver impairment and potential drug interactions. Common adverse effects include gastrointestinal disturbances, headache, and rash, while rare but serious side effects may involve hepatotoxicity and congestive heart failure exacerbation. Due to its potential for significant drug interactions, careful review of concomitant medications is essential before initiating therapy. Itrawave 100 Capsule should be used under medical supervision, with dosage adjustments based on the severity of infection and patient response, ensuring optimal therapeutic outcomes while minimizing risks.